167 related articles for article (PubMed ID: 36566402)
21. Hairy cell leukemia: an elusive but treatable disease.
Wanko SO; de Castro C
Oncologist; 2006; 11(7):780-9. PubMed ID: 16880237
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
Ravandi F; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Koller C; Challagundla P; York S; Brandt M; Luthra R; Burger J; Thomas D; Keating M; Kantarjian H
Blood; 2011 Oct; 118(14):3818-23. PubMed ID: 21821712
[TBL] [Abstract][Full Text] [Related]
23. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
24. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.
Dearden CE; Matutes E; Hilditch BL; Swansbury GJ; Catovsky D
Br J Haematol; 1999 Aug; 106(2):515-9. PubMed ID: 10460614
[TBL] [Abstract][Full Text] [Related]
26. My treatment approach to hairy cell leukemia.
Naik RR; Saven A
Mayo Clin Proc; 2012 Jan; 87(1):67-76. PubMed ID: 22212971
[TBL] [Abstract][Full Text] [Related]
27. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
29. Advances in the treatment of hairy-cell leukaemia.
Mey U; Strehl J; Gorschlüter M; Ziske C; Glasmacher A; Pralle H; Schmidt-Wolf I
Lancet Oncol; 2003 Feb; 4(2):86-94. PubMed ID: 12573350
[TBL] [Abstract][Full Text] [Related]
30. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
31. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
32. [Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia].
Terasaki Y; Okumura H; Hirose A; Ishiura Y; Yokawa S; Saito K; Nakao S
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1885-8. PubMed ID: 18030031
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
34. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
Hacioglu S; Bilen Y; Eser A; Sivgin S; Gurkan E; Yildirim R; Aydogdu I; Dogu MH; Yilmaz M; Kayikci O; Tombak A; Kuku I; Celebi H; Akay MO; Esen R; Korkmaz S; Keskin A
Hematol Oncol; 2015 Dec; 33(4):192-8. PubMed ID: 25393847
[TBL] [Abstract][Full Text] [Related]
35. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Hoffman MA; Janson D; Rose E; Rai KR
J Clin Oncol; 1997 Mar; 15(3):1138-42. PubMed ID: 9060556
[TBL] [Abstract][Full Text] [Related]
36. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia.
Yang MH; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):54-8. PubMed ID: 11310372
[TBL] [Abstract][Full Text] [Related]
37. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience.
Broccoli A; Argnani L; Nanni L; Terragna C; Sabattini E; Gabrielli G; Stefoni V; Pellegrini C; Casadei B; Morigi A; Lolli G; Carella M; Coppola PE; Zinzani PL
Am J Hematol; 2021 Oct; 96(10):1204-1210. PubMed ID: 34245477
[TBL] [Abstract][Full Text] [Related]
38. Hairy cell leukemia: clinical, pathological and ultrastructural findings in Asian-Indians.
Chatterjee T; Panigrahi I; Mahapatra M; Pati HP; Kumar R; Naithani R; Wadhwa S; Choudhry VP; Saxena R
Indian J Cancer; 2008; 45(2):41-4. PubMed ID: 18626146
[TBL] [Abstract][Full Text] [Related]
39. Development of cladribine at Scripps for hairy cell leukemia and current results.
Torrey ML; Sigal DS; Saven A
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():29-33. PubMed ID: 21504293
[TBL] [Abstract][Full Text] [Related]
40. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Kreitman RJ; Wilson W; Calvo KR; Arons E; Roth L; Sapolsky J; Zhou H; Raffeld M; Stetler-Stevenson M
Clin Cancer Res; 2013 Dec; 19(24):6873-81. PubMed ID: 24277451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
